This inventor holds 1 USPTO granted patent. Top assignees: The Asan Foundation, University of Ulsan Foundation for Industry Cooperation. Active years: 2025.
Company Filing History:
1 out of 84 
1 out of 94 
Years Active: 2025
Title: Sin Hwang: Innovator in Hepatocellular Carcinoma Diagnosis
Introduction
Sin Hwang is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of medical diagnostics, particularly in the early detection of hepatocellular carcinoma, a common type of liver cancer. His innovative work focuses on the use of biomarkers to improve diagnostic accuracy and patient outcomes.
Latest Patents
Sin Hwang holds a patent for a groundbreaking invention titled "Biomarker cereblon for diagnosing hepatocellular carcinoma, and novel monoclonal antibody specific thereto." This patent outlines the use of cereblon (CRBN) as a biomarker for diagnosing hepatocellular carcinoma. The invention includes a composition and a kit designed for diagnosing or predicting the prognosis of this cancer by utilizing CRBN. The patent also introduces two novel monoclonal antibodies that specifically bind to CRBN, along with hybridoma cells that produce these antibodies. The expression level difference of CRBN protein allows for early diagnosis of hepatocellular carcinoma and offers better predictive capabilities than previous methods, which relied on microvascular invasion.
Career Highlights
Throughout his career, Sin Hwang has been associated with prominent institutions, including the University of Ulsan Foundation for Industry Cooperation and The Asan Foundation. His work has been instrumental in advancing the understanding and diagnosis of hepatocellular carcinoma, contributing to improved patient care.
Collaborations
Sin Hwang has collaborated with Kyung Jin Lee, who has played a significant role in his research endeavors. Their partnership has fostered innovation and development in the field of cancer diagnostics.
Conclusion
Sin Hwang's contributions to the medical field, particularly in the diagnosis of hepatocellular carcinoma, highlight the importance of innovation in healthcare. His work with biomarkers and monoclonal antibodies represents a significant advancement in early cancer detection and prognosis evaluation.